Sun Pharma expects 18-20 per cent growth in 2013-14
The third largest drug maker in India expects to grow by 18-20 per cent in the current fiscal.
Mumbai, May 28, 2013: Sun Pharmaceutical Industries, the third largest drug maker in India b sales expects the revenue growth of 18-20 per cent in the current fiscal.
The company also plans to spend over Rs 8 billion rupees (US$ 144 million) on capital expenditure and file about 25 generic drug applications for approval in the United States.
It is worth mentioning here that the company recently reported a 23.4 per cent rise in net profit during the fourth quarter ending March 2013 at Rs 10.12 billion.